Alpa Laboratories (NSE:ALPA) ROCE %: 6.79% (As of Mar. 2026)

What is Alpa Laboratories ROCE %?

Alpa Laboratories NSE:ALPA -0.35% 75 ROCE % is 6.79% as of Mar. 2026. GuruFocus rates NSE:ALPA with a GF Score™ of 75/100 and a GF Value™ of ₹92.74 (Modestly Undervalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Alpa Laboratories's annualized ROCE % for the quarter that ended in Mar. 2026 was 6.79%.

Alpa Laboratories (NSE:ALPA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Alpa Laboratories ROCE % Related Terms

Alpa Laboratories ROCE % Historical Data

* Premium members only.

The historical data trend for Alpa Laboratories's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alpa Laboratories ROCE % Chart

Alpa Laboratories Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

ROCE %

Get a 7-Day Free Trial

16.99

12.22

14.39

15.69

9.28

Alpa Laboratories Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															4.75	26.86	0.31	3.78	6.79

75GF Score

Alpa Laboratories Ltd NSE:ALPA

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Alpa Laboratories ROCE % Calculation

Alpa Laboratories's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	169.552	/	( ( (2226.276 - 467.003)	+	(2421.447 - 525.274) )	/ 2 )
	=	169.552	/	( (1759.273	+	1896.173)	/ 2 )
	=	169.552	/	1827.723
	=	9.28 %

Alpa Laboratories's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	128.748	/	( ( (0 - 0)	+	(2421.447 - 525.274) )	/ 1 )
	=	128.748	/	( ( 0	+	1896.173 )	/ 1 )
	=	128.748	/	1896.173
	=	6.79 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 6.79% mean?

Alpa Laboratories (NSE:ALPA) has a ROCE % of 6.79% as of Mar. 2026.

Is Alpa Laboratories' ROCE % too high?

Alpa Laboratories' current ROCE % is 6.79%. The Drug Manufacturers industry median ROCE % is 7.00. Alpa Laboratories' value of 6.79% is 2.9% below this industry median. Overall, Alpa Laboratories has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Alpa Laboratories' ROCE % compare to ZTS?

Alpa Laboratories' ROCE % of 6.79% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Alpa Laboratories' value of 6.79% is 2.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpa Laboratories's current ROCE % of 6.79% is 2.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpa Laboratories's current ROCE % is 6.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Alpa Laboratories stock overvalued right now?

Based on GuruFocus' analysis, Alpa Laboratories (NSE:ALPA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹92.74, compared to a current price of ₹68.50 — trading 26.1% below its estimated fair value. The current ROCE % is 6.79% and 2.9% below the Drug Manufacturers industry median of 7.00. Alpa Laboratories' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Alpa Laboratories (NSE:ALPA), the current ROCE % is 6.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alpa Laboratories (NSE:ALPA) Overvalued in 2026?

Based on GuruFocus' analysis, Alpa Laboratories stock appears to be undervalued. The current stock price of ₹68.50 is trading 26.1% below its estimated GF Value™ of ₹92.74. GuruFocus considers Alpa Laboratories to be Modestly Undervalued.

Key valuation signals for NSE:ALPA:

ROCE %: 6.79%
GF Value™: ₹92.74 vs. price of ₹68.50 (26.1% below fair value)
GF Score™: 75/100 with 6 warning signs
Industry Position: 2.9% below the Drug Manufacturers median

No single metric tells the full story. See the NSE:ALPA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alpa Laboratories Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies NSE:BALAXI BOM:524202 BOM:524824 BOM:540686 BOM:532384 BOM:524518 BOM:506128 BOM:524654 BOM:524506 BOM:530317 XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges 532878:India

Address 33/2, A.B. Road, Pigdamber, Rau, Indore, MP, IND, 453446

Website https://www.alpalabs.in

Alpa Laboratories Ltd is an India-based pharmaceutical company. It operates in the drug and chemical business segment. The company manufactures and markets pharmaceuticals and related products. It sells products like liquid injection, dry powder injection, tablets, capsules, and ointments.

75GF Score

Get the complete analysis for NSE:ALPA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹68.50

Price

₹92.74

GF Value

View NSE:ALPA Analysis

See ROCE % data for all stocks →